Adrenocortical Carcinoma — Cabozantinib in Advanced Adrenocortical Carcinoma
Citation(s)
A Multicenter, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Cabozantinib in Advanced (Unresectable or Metastatic) Adrenocortical Carcinoma